The role of the brain reward system in depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 25, Issue 4, 2001, Pages 781-823

  Naranjo, Claudio A ^a,b,c   Tremblay, Lescia K ^a,c   Busto, Usoa E ^a,b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amphetamine; Anhedonia; Brain reward system; Depression; Dopamine; Major depressive disorder

Indexed keywords

DEXAMPHETAMINE; DOPAMINE; HYDROMORPHONE;

ANHEDONIA; BEHAVIOR; COGNITION; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRIVE; ENDOCRINE SYSTEM; HEART RATE; HUMAN; MONOAMINERGIC SYSTEM; MOTIVATION; NEUROBIOLOGY; PATHOPHYSIOLOGY; REVIEW; REWARD;

AMPHETAMINE; ANIMALS; BRAIN; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER; HUMANS; REWARD;

EID: 0035040136     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00156-7     Document Type: Article

References (274)

1. Effects of dopamine antagonists and accumbens dopamine depletions on time-constrained progressive-ratio performance
2. Neurotrophins and depression
3. The biological, social and clinical bases of drug addiction: Commentary and debate
4. Mood disorders
5. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
6. Linking mind and brain in the study of mental illnesses: A project for a scientific psychopathology
7. Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study
8. Age-related cognitive deficits mediated by changes in the striatal dopamine system
9. A dopamine D1 agonist elevates self-stimulation thresholds: Comparison to other dopamine-selective drugs
10. Neuropharmacological mechanisms of drug reward: Beyond dopamine in the nucleus accumbens
11. Chronic mild stress has no effect on responding by rats for sucrose under a progressive ratio schedule
12. The dopaminergic hyper-responsiveness of the shell of the nucleus accumbens is hormone-dependent
13. Modulation of feeding-induced activation of mesolimbic dopamine transmission by appetitive stimuli and its relation to motivational state
14. The functional neuroanatomy of major depression: An f-MRI study using an emotional activation paradigm
15. A two-separate-motivational-systems hypothesis of opioid addiction
16. Regional cerebral blood flow in depression measured by positron emission tomography: The relationship with clinical dimensions
17. Antidepressant effects of ketamine in depressed patients
18. Substantia nigra 6-OHDA lesions mimic striatopallidal disruption of syntactic grooming chains: A neural systems analysis of sequence control
19. Food reward: Brain substrates of wanting and liking
20. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?
21. Dopaminergic and opioidergic mediations of tricyclic antidepressants in the learned helplessness paradigm
22. Reversal of learned helplessness by morphine in rats: Involvement of a dopamine mediation
23. Behavioral economics: A novel experimental approach to the study of drug dependence
24. Dopamine functions in appetitive and defensive behaviours
25. Beta-endorphin and beta-lipotropin plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders
26. Naltrexone blockade of nicotine effects in cigarette smokers
27. Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men
28. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers
29. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
30. Functional magnetic resonance imaging of brain reward circuitry in the human
31. Acute effects of cocaine on human brain activity and emotion
32. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine
33. Effect of sertraline on regional metabolic rate in patients with affective disorder
34. The effect of naloxone on adrenocorticotropin and cortisol release: Evidence for a reduced response in depression
35. Glutamate-dopamine interactions in the ventral striatum: Role in locomotor activity and responding with conditioned reinforcement
36. Self-administration of intravenous amphetamine: Effect of nucleus accumbens CCKB receptor activation on fixed-ratio responding
37. Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective
38. Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments
39. Dose-dependent aversive and rewarding effects of amphetamine as revealed by a new place conditioning apparatus
40. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: Possible role of the “hedonic” dopamine synapse
41. Dopaminergic activity in depressed smokers
42. Neurobiological dimensions of depression and mania
43. Acquisition of i.v. Amphetamine and cocaine self-administration in rats as a function of dose
44. Discriminative stimulus effects of caffeine and benzamphetamine in amphetamine-trained volunteers
45. The discriminitive stimulus and subjective effects of d-amphetamine in humans
46. The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans
47. The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol, and d-amphetamine in humans
48. Phenylpropanolamine: Reinforcing and subjective effects in normal human volunteers
49. Comparison of mesocorticolimbic neuronal responses during cocaine and heroin self-administration in freely moving rats
50. Monoamine dysfunction and the pathophysiology and treatment of depression
51. Changes in sleep architecture following chronic mild stress
52. Limbic activation during cue-induced cocaine craving
53. Rational drug use in the treatment of depression
54. Plasma cortisol and $-endorphin immunoreactivity in nonmajor and major depression
55. Assessment of the abuse liability of buspirone in recreational sedative users
56. Amphetamine self-administration by humans: Modulation by contingencies associated with task performance
57. Prolactin response to d-fenfluramine and suicidal behavior in depressed patients
58. Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant
59. Dopamine D2 receptors in depression measured with single photon emission computed tomography
60. Rate of increase of plasma drug level influences subjective response in humans
61. Subjective and behavioral effects of diazepam depend on its rate of onset
62. Testing the abuse liability of anxiolytic and hypnotic drugs in humans
63. The reinforcing properties of amphetamine in overweight subjects and subjects with depression
64. Executive deficits in major depression
65. Role of dopamine in the behavioral actions of nicotine related to addiction
66. Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: Implications for the psychobiology of depression
67. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area
68. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system
69. Dissociation in prefrontal cortex of affective and attentional shifts
70. The neuroendocrine and behavioral response to dextroamphetamine in normal individuals
71. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder
72. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli
73. Changes in dopamine receptor mRNA expression following chronic mild stress and chronic antidepressant treatment
74. Dopamine and depression - Striatal dopamine D2 receptor SPECT before and after antidepressant therapy
75. Dissociable neural responses in human reward systems
76. Abnormal neural response to feedback on planning and guessing tasks in patients with unipolar depression
77. Abuse liability assessment of anxiolytics/hypnotics: Rationale and laboratory lore
78. Diltiazem, a calcium channel antagonist, partly attenuates the effects of dextroamphetamine in healthy volunteers
79. Pharmacokinetic considerations in abuse liability evaluation
80. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans
81. Selective destruction of brain serotonin neurons by 5,7 dihydroxytryptamine increases responding for a conditioned reward
82. Effects of d-fenfluramine and metergoline on responding for conditioned reward and the response potentiating effect of nucleus accumbens d-amphetamine
83. Methods for the assessment of abuse liability psychomotor stimulants and anorectic agents in humans
84. Reliability, validity and clinical application of the visual analogue mood scale
85. Chronic mild stress and sucrose consumption: Validity as a model of depression
86. Changes in pupil reaction to light in melancholic patients
87. Hypofrontality and negative symptoms in major depressive disorder
88. A chronic stress that impairs reactivity in rats also decreases dopaminergic transmission in the nucleus accumbens: A microdialysis study
89. Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation
90. Blunted left cingulate activation in mood disorder subjects during a response interference task (the Stroop)
91. Multiple variable interval schedule behavior in humans: Effects of ethanol, mood, and reinforcer size on responding maintained by monetary reinforcement
92. Biological and behavioral responses to d-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers
93. A role for AMPA kainate receptors in conditioned place preference induced by diazepam in the rat
94. Human drug self-administration: Double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo
95. Predicting the dependence liability of stimulant drugs
96. Failure to change exploration or saccharin preference in rats exposed to chronic mild stress
97. Vigilance performance in Parkinson's disease and depression
98. NMDA, but not dopamine D2, receptors in the rat nucleus accumbens are involved in guidance of instrumental behavior by stimuli predicting reward magnitude
99. Effect of amphetamine on extracellular acetylcholine and monoamine levels in subterritories of the rat medial prefrontal cortex
100. Amphetamine microinfusion in the dorso-ventral axis of the prefrontal cortex differentially modulates dopamine neurotransmission in the shell-core subterritories of the nucleus accumbens
101. Anhedonia-a general nosology surmounting correlate of a dysfunctional dopaminergic reward system?
102. Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans
103. Drug self-administration in abuse liability evaluation
104. Anhedonia in schizophrenia: Longitudinal analyses
105. Opioid reward mechanisms: A key role in drug abuse?
106. Neostriatal rCBF correlates of psychomotor slowing in patients with major depression
107. Delay activity of orbital and lateral prefrontal neurons of the monkey varying with different rewards
108. The Addiction Research Center Inventory: Standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pirahexl and chloropromazine
109. Measurement of reinforcement in depression: A pilot study
110. Modeling drug dependence behaviors for animal and human studies
111. Intra-medial prefrontal cortex injections of scopolamine increase instrumental responses for cocaine: An intravenous self-administration study in rats
112. The role of nucleus accumbens dopamine in motivated behavior: A unifying interpretation with special reference to reward-seeking
113. Nicotine and endogenous opioids: Toward specific pharmacotherapy
114. Historical perspectives on the use of subjective effects measures in assessing the abuse potential of drugs
115. History of abuse liability testing in humans
116. Human abuse liability assessment by measurement of subjective and physiological effects. Testing for abuse liability of drugs in humans
117. Cocaine plasma concentration: Relation to physiological and subjective effects in humans
118. Amphetamine depresses excitatory synaptic transmission via serotonin receptors in the ventral tegmental area
119. Amphetamine blocks long-term synaptic depression in ventral tegmental area
120. Nicotinic receptors in the brain: Correlating physiology with function
121. Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers
122. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders
123. Endogenomorphic depression: A conceptual and terminological revision
124. Dopamine D2 receptor binding before and after treatment of major depression measured by [I-123] IBZM SPECT
125. 3 preferring compounds on conditioned place preference and intracranial self-stimulation in the rat
126. Evidence for striatal dopamine release during a video game
127. Cellular and molecular mechanisms of drug dependence
128. Drug addiction: The yin and yang of hedonic homeostasis
129. Hedonic valence, dopamine and motivation
130. Drug abuse: Hedonic homeostatic dysregulation
131. Neurocircuitry targets in ethanol reward and dependence
132. Methylphenidate hydrochloride as an antidepressant: Controversy, case studies and review
133. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine
134. CART peptides: Novel addiction-and feeding-related neuropeptides
135. Striatal dopamine transporter density in major depression
136. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments
137. SPECT imaging of striatal dopamine release after amphetamine challenge
138. Single photon emission computerized tomography. Imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
139. Dopamine D3 receptor agents as potential new medications for drug addiction
140. Stress versus depression
141. Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation
142. Evidence for a biochemical lesion in depression
143. Pharmacological magnetic resonance imaging: A new application for functional MRI
144. Clinical applications of functional MRI in neuropsychiatry
145. Increased cerebrospinal fluid glutamine levels in depressed patients
146. Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations
147. Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls
148. Amphetamine, but not methylphenidate, predicts antidepressant efficacy
149. Previous exposure to amphetamine increases incentive to obtain the drug: Long-lasting effects revealed by the progressive ratio schedule
150. Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving
151. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors
152. Facilitating compliance with antipsychotic medication
153. Involvement of acetylcholine in the nucleus accumbens in cocaine reinforcement
154. Cognitive and behavioral correlates of depression in learning-disabled and nonlearning disabled adult students
155. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid receptor gene
156. Cingulate function in depression: A potential predictor of treatment response
157. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness
158. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects
159. Regulation of neurotransmitter interactions in the ventral striatum
160. Cocaine is self-administered into the shell region of the nucleus accumbens in Wistar Rats
161. Attenuation of some subjective effects of amphetamine following tyrosine depletion
162. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain
163. Dopamine and sexual behavior
164. The synaptic framework for chemical signaling in nucleus accumbens
165. Naloxone-induced pituitary-adrenal activation does not differ in patients with depression, obsessive-compulsive disorder, and healthy controls
166. Re-evaluation of the role of dopamine in intracranial self-stimulation using in vivo microdialysis
167. Are all antidepressants the same?
168. 2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats
169. Covariation of activity in habenula and dorsal raphe nuclei following tryptophan depletion
170. Alnespirone (S 20499), an agonist of 5-HT1a receptors, and imipramine have similar activity in a chronic mild stress model of depression
171. Rewarding effects of opiates are absent in mice lacking the receptor for substance P
172. The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats
173. DST studies in psychotic depression: A meta-analysis
174. The neurobiology of depression
175. Firing rate of nucleus accumbens neurons is dopamine-dependent and reflects the timing of cocaine-seeking behavior in rats on a progressive ratio schedule of reinforcement
176. Intracranial self-stimulation and sucrose intake differ as hedonic measures following chronic mild stress: Interstrain and interindividual differences
177. Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man
178. Drug addiction and drug abuse
179. Positive reinforcement produced by electrical stimulation of the septal area and other regions of the rat brain
180. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans
181. Glial reduction in the subgenual prefrontal cortex in mood disorders
182. The role of stress in the pathophysiology of the dopaminergic system
183. The rewarding properties of NMDA and MK-801 (dizocilpine) as indexed by the conditioned place preference paradigm
184. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine
185. Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress
186. Relationships between thyroid hormone and antidepressant responses to total sleep deprivation in mood disorder patients
187. Remission and residual symptomatology in major depression
188. Residual symptoms after partial remission: An important outcome in depression
189. Effects of chronic naloxone treatment on brain-stimulation reward
190. Parkinsonian patients report blunted subjective effects of methylphenidate
191. Posttraumatic stress and depression. A neurochemical anatomy of the learned helplessness animal model
192. Neurobiological correlates of positive emotional states: Dopamine, anticipation, and reward
193. Acetylcholine receptors containing the beta-2 subunit are involved in the reinforcing properties of nicotine
194. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: Plasmalemmal dopamine transporter versus vesicular monoamine transporter
195. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs
196. Orbital and medial prefrontal cortex and psychostimulant abuse: Studies in animal models
197. Modulation of the discriminative stimulus effects of d-amphetamine by mu and kappa opioids in squirrel monkeys
198. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
199. Intracerebro-ventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats
200. 2 agonists on brain stimulation reward
201. Diazepam and triazolam self-administration in sedative abusers: Concordance of subject ratings, performance and drug self-administration
202. The neural basis of drug craving: An incentive-sensitization theory of addiction
203. Cocaine self-administration in dopamine-transporter knockout mice
204. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor
205. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam
206. The dexamethasone suppression test in patients with mood disorders
207. The behavioral neurochemistry of motivation: Methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine
208. Behavioral functions of nucleus accumbens dopamine: Empirical and conceptual problems with the anhedonia hypothesis
209. Decreased reactivity to sweetness following chronic exposure to mild unpredictable stress or acute administration of pimozide
210. Site of opioid action in the human brain: Mu and kappa agonist subjective and cerebral blood flow effects
211. Role of dopamine receptor subtypes in the acquisition of a testosterone conditioned place preference in rats
212. Reward processing in primate orbitofrontal cortex and basal ganglia
213. Dopamine neurons and their role in reward mechanisms
214. Predictive reward signal of dopamine neurons
215. A neural substrate of prediction and reward
216. Biobehavioral effects of psychoactive drugs (Chapter 16)
217. Amphetamine: Effects on catecholamine systems and behavior
218. Clinical and psychometric correlates of dopamine D2 binding in depression
219. Dual effects of d-amphetamine on dopamine neurons mediated by dopamine and non-dopamine receptors
220. Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion
221. Dopamine in food reward
222. Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine
223. Nicotine-induced limbic cortical activation in the human brain: A functional MRI study
224. Amphetamine injections into the nucleus accumbens enhance the reward of stimulation of the subiculum
225. Differences in receptor system participation between nicotine- and cocaine-induced dopamine overflow in nucleus accumbens
226. 1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse
227. Neuroanatomical correlates of hunger and satiation in humans using positron emission tomography
228. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model
229. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline
230. The orbitofrontal cortex: Neuronal activity in the behaving monkey
231. Activation of the human brain by monetary reward
232. Response to d-amphetamine is altered in Major Depressive Disorder (MDD)
233. Reward-related neuronal activity during go-nogo task performance in primate orbitofrontal cortex
234. Drug preference and mood in humans: Preference for d-amphetamine and subject characteristics
235. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system
236. 9- tetrahydrocannabinol in mice
237. Sexual motivation: Involvement of endogenous opioids in the ventral tegmental area
238. Catecholamines and endogenous opioids in ventral tegmental self-stimulation reward
239. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: A critical review
240. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism
241. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors
242. Addiction, a disease of compulsion and drive: Involvement of orbitofrontal cortex
243. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans
244. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: Implications in addiction
245. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels
246. Relationship between subjective effects of cocaine and dopamine transporter occupancy
247. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate
248. Effects of dopaminergic drugs on delayed reward as a measure of impulsive behavior in rats
249. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans
250. Regional brain metabolic activation during craving elicited by recall of previous drug experiences
251. Blockade of cocaine-induced increases in adrenocorticotrophic hormone and cortisol does not attenuate the subjective effects of smoked cocaine in humans
252. Ketoconazole attenuates the cortisol response but not the subjective effects of smoked cocaine in humans
253. Rats selectively bred for high and low swim-test activity show differential responses to dopaminergic drugs
254. Effects of antidepressant drugs on rats bred for low activity in the swim test
255. Stimulus effects of d-amphetamine II: DA, NE, and 5-HT mechanisms
256. Chronic mild stress-induced anhedonia: A realistic animal model of depression
257. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation
258. Neurobiology of addiction
259. Neuroleptics and operant behavior: The anhedonia hypothesis
260. Addictive drugs and brain stimulation reward
261. Drug-activation of brain reward pathways
262. Neuroleptic-induced “anhedonia” in rats: Pimozide blocks reward quality of food
263. Mesolimbic neuronal activity across behavioral states
264. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor
265. Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission
266. Effects of naltrexone on food intake and changes in subjective appetite during eating: Evidence for opioid involvement in the appetizer effect
267. Endomorphins: Novel endogenous u-opiate receptor agonists in regions of high u-opiate receptor density
268. Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: A microdialysis study
269. Nicotine and heroin augment cocaine-induced dopamine overflow in nucleus accumbens
270. Opioid regulation of hypothalamic-pituitary-adrenal function in depression